

Maya Ferreira, PhD

Biostatistician | Clinical Trial Design & Survival Analysis

✉ maya.ferreira@nexahealth.example 📞 (617) 555-0148 📍 Cambridge, MA 🔗 [linkedin.com/in/mayaferreira-biostat](https://www.linkedin.com/in/mayaferreira-biostat) 🌐 github.com/mferreira-stat

Summary

Biostatistician with 9 years of experience leading statistical strategy for Phase I–III oncology and cardiovascular trials. Deep expertise in adaptive trial design, time-to-event methods, and regulatory submissions, with a track record of authoring statistical analysis plans (SAPs) accepted by FDA and EMA reviewers. Fluent in R and SAS validation workflows under GxP; regularly bridges biostatistics, clinical operations, and data management to keep studies on schedule and audit-ready.

Core Skills

Software

R (tidyverse, survival, nlme, rstan), SAS (Base, STAT, Macro), Python (pandas, lifelines), SQL, Shiny, Git

Statistical Methods

Survival & competing-risks analysis, mixed-effects models, group-sequential & adaptive designs, Bayesian hierarchical models, propensity-score matching, multiple imputation

Clinical & Regulatory

SAP authorship, CDISC SDTM/ADaM standards, DSMB reporting, FDA/EMA briefing packages, ICH E9(R1) estimands, TLF programming, CSR statistical sections

Professional Experience

Senior Biostatistician

2021 – Present

Nexa Therapeutics

Cambridge, MA

- Lead biostatistician for a 640-patient Phase III adaptive trial in metastatic colorectal cancer; designed the group-sequential stopping boundaries that let the DSMB halt the control arm 4 months early for efficacy.
- Authored the SAP and estimand strategy under ICH E9(R1) for a cardiovascular outcomes trial spanning 38 sites; the submission cleared FDA statistical review with zero major deficiencies.
- Built a validated R/Shiny survival-analysis dashboard (Kaplan-Meier, Cox PH, competing risks) now used by 12 clinical programs, cutting DSMB report turnaround from 3 weeks to 4 days.

Biostatistician II

2018 – 2021

Synapse Clinical Research

Boston, MA

- Programmed and validated TLFs (tables, listings, figures) for six Phase II oncology studies using SAS macros aligned to CDISC ADaM specifications.
- Implemented a Bayesian hierarchical model for a basket trial across 5 tumor types, enabling early borrowing of strength across cohorts and a 20% reduction in required enrollment.
- Partnered with data management to redesign edit-check logic, reducing query rates on time-to-event endpoints by 31%.

Statistical Analyst

2016 – 2018

Vertex Health Analytics

Providence, RI

- Supported real-world evidence studies using propensity-score matching and multiple imputation on claims and EHR data for post-marketing safety surveillance.
- Automated monthly safety-signal summaries in R, replacing a manual Excel process and eliminating recurring transcription errors flagged in a prior audit.

Education

Ph.D. in Biostatistics

2016

Boston University

Boston, MA

Dissertation: Flexible modeling of recurrent-event data in oncology trials with informative censoring

M.S. in Statistics

2012

University of Massachusetts Amherst

Amherst, MA

Certifications & Publications

- SAS Certified Advanced Programmer for SAS 9; ICH E9(R1) Estimands & Sensitivity Analysis (Nimbus Institute, 2022)
- Ferreira, M. et al. *Group-sequential design for basket trials with borrowed strength across cohorts*. Journal of Biopharmaceutical Statistics (2023)
- Ferreira, M., Okafor, D. *Comparing Cox and flexible parametric models under informative censoring in oncology*. Clinical Trials Quarterly (2021)